Huons Meditech to Hold 'Urological Extracorporeal Shock Wave Therapy Symposium'

Introduction of Clinical Application Cases of 'IMPO88 Plus' for Medical Professionals

Huons Meditech, a medical device company under the Huons Group, will hold an academic event for medical professionals to present new clinical cases using extracorporeal shock wave therapy for additional indications.

Huons Meditech will hold the 'CP&CPPS Treatment Symposium,' an academic event for medical professionals, on the 28th. Photo by Huons Meditech

On June 24, Huons Meditech announced that it will host the 'Chronic Prostatitis & Chronic Pelvic Pain Syndrome Treatment Symposium' (CP&CPPS Treatment Symposium), an academic event focused on clinical cases using its urological extracorporeal shock wave therapy device, on June 28 at Seoul Dragon City in Yongsan-gu, Seoul.

Huons Meditech, which holds the top market share in extracorporeal shock wave lithotripters in Korea, explained that the event is designed to academically highlight the excellence of its new product, 'IMPO88 Plus,' to urological medical professionals.

'IMPO88 Plus' is the successor model to Huons Meditech's erectile dysfunction shock wave therapy device, 'IMPO88.' After clinical trials at Seoul St. Mary's Hospital demonstrated its efficacy in treating chronic prostatitis and chronic pelvic pain syndrome, Huons Meditech launched 'IMPO88 Plus' in April with these additional indications.

Notably, 'IMPO88 Plus' is the only extracorporeal shock wave therapy device in Korea that has clinically proven efficacy for both inflammatory and non-inflammatory chronic pelvic pain syndrome. By inhibiting the activation of 'inflammasomes,' the inflammatory cells found in chronic inflammatory patients, the device can reduce or even eliminate the need for antibiotic prescriptions during treatment. This increases patient satisfaction and can enhance the effectiveness of combination therapies.

This symposium will invite domestic urology medical professionals to introduce clinical application cases of 'IMPO88 Plus' and to academically review its effectiveness.

Professor Hong Sungkyu of Seoul National University Bundang Hospital will serve as chair, with Professor Park Heungjae of Kangbuk Samsung Hospital and Professor Shin Dongho of Seoul St. Mary's Hospital as speakers. In addition, Han Byungkyu, Director of the Urological Endoscopy Certification Committee of the Korean Urological Association, will share his expertise on 'know-how in urological endoscope disinfection management.'

Lee Jinseok, CEO of Huons Meditech, stated, "We hope this symposium will serve as an opportunity to showcase the competitiveness of the next-generation extracorporeal shock wave therapy device, IMPO88 Plus, and open new horizons in the field of urology. We will continue to do our best to share high-quality clinical know-how with medical professionals through future symposiums."